

6 August 2026

Argent BioPharma Welcomes Commencement of U.S. Veterinary Development Programme for CannEpil®

Highlights:

- **Splash Beverage Group commences the U.S. veterinary development programme for CannEpil®**
- **Lupvindol Biosciences appointed to lead pharmaceutical development and FDA regulatory strategy**
- **Programme to initially focus on companion-animal oncology and chronic pain management**
- **Development to progress through the U.S. FDA Center for Veterinary Medicine (FDA CVM) via the Investigational New Animal Drug (INAD) and Conditional Approval pathways**
- **Programme led by Dr. Hunter Land, former GW Pharmaceuticals executive involved in the development of Epidiolex® and Sativex®**
- **Represents the first operational milestone following Argent BioPharma's recently announced expansion of CannEpil® into veterinary healthcare**


Veterinary Development Programme Commences

Argent BioPharma Ltd (ASX: RGT) (Argent or the Company) is pleased to advise shareholders that **Splash Beverage Group (Splash)**, the Company's exclusive global licensing partner for CannEpil®, has announced the commencement of its U.S. veterinary pharmaceutical development programme through a strategic collaboration with **Lupvindol Biosciences Ltd.**

The appointment represents the first operational milestone following the recently announced expansion of CannEpil® into veterinary applications and establishes a defined regulatory development pathway for the product within the United States animal health market.

The programme will initially focus on the development of CannEpil® for **companion-animal oncology** and **chronic pain management**, with canine applications expected to form the first stage of development.

Development activities will progress through the **U.S. Food and Drug Administration Center for Veterinary Medicine (FDA CVM)**, commencing with the **Investigational New Animal Drug (INAD)** process before progressing toward potential Conditional Approval.



Experienced Cannabinoid Pharmaceutical Development Team

The veterinary programme will be led by **Dr. Hunter Land**, Chief Executive Officer of Lupvindol Biosciences, together with an experienced cannabinoid pharmaceutical development team.

Dr. Land was the first full-time U.S. research and development employee of GW Pharmaceuticals and played an important role in the development of **Epidiolex®**, the world's first FDA-approved plant-derived cannabinoid medicine, as well as **Sativex®**.

The broader Lupvindol team brings extensive experience in cannabinoid pharmaceutical development, FDA regulatory strategy, pre-clinical and clinical study design, product development and commercialisation.

The Company believes the appointment of such an experienced cannabinoid pharmaceutical development team significantly strengthens the execution capability of the veterinary programme and supports the long-term commercial opportunity for CannEpil®.

Strategic Importance

The commencement of the veterinary programme represents the successful execution of the commercial strategy announced by Argent BioPharma following the expansion of the CannEpil® licensing agreement into veterinary medicine.

Importantly, Argent BioPharma continues to retain ownership of all existing and future CannEpil® intellectual property, manufacturing know-how and regulatory assets, while participating in the long-term commercial success of the product through royalties across both the human and veterinary healthcare markets.

The Company believes the appointment of an experienced development partner, together with the commencement of a defined FDA regulatory pathway, represents an important value-enhancing milestone for the CannEpil® platform and further validates the strategic expansion of the product beyond its original neurological indications.

Roby Zomer, Chairman, commented:

"We are extremely pleased to see the rapid execution of the strategy following the recent expansion of CannEpil® into veterinary healthcare.

The appointment of Dr. Hunter Land and the Lupvindol Biosciences team brings one of the industry's most experienced cannabinoid pharmaceutical development groups to the programme. Their involvement, including direct experience with the development of Epidiolex® and Sativex®, provides significant scientific and regulatory expertise as CannEpil® advances through the FDA veterinary pathway.

Importantly, this milestone demonstrates that the global licensing strategy is already translating into tangible operational progress. While Argent retains ownership of the CannEpil® intellectual property, manufacturing capabilities and long-term royalty participation, our licensing partner is actively executing the next phase of development, creating additional opportunities to expand the value of the CannEpil® platform for shareholders."


—Ends—

Argent BioPharma Ltd
Suite 1, 295 Rokeby Road
Subiaco, WA 6008, Australia

 +61 8 6555 2950

 info@argentbiopharma.com





Authorised for release by the board of directors, for further information please contact:

Argent BioPharma

Roby Zomer

Chairman

+61 8 6555 2950

info@argentbiopharma.com

Argent BioPharma

Rowan Harland

Company Secretary

+61 8 6555 2950

info@argentbiopharma.com

About Argent BioPharma

Argent BioPharma Ltd. (ASX: RGT) is a revenue-generating specialty biopharmaceutical company focused on building a differentiated immune-modulation intellectual property platform through the development, commercialisation and strategic licensing of innovative therapeutics. The Company's portfolio is anchored by CimetrA®, a first-in-class immune-modulating platform targeting inflammatory and autoimmune diseases, supported by proprietary NanoBodies™ and peptide technologies, advanced nano-delivery systems and EU-GMP manufacturing capabilities. Following the global licensing of CannEpil®, Argent BioPharma has adopted a capital-efficient strategy that combines proprietary intellectual property, commercial-stage products, strategic licensing, manufacturing services and recurring royalty income to create long-term shareholder value. With a focused pipeline of immune-modulating technologies, a growing portfolio of proprietary pharmaceutical assets and an expanding commercial platform, Argent BioPharma is positioning itself as a next-generation specialty pharmaceutical company with a clear pathway toward expansion into the United States capital markets.

About Splash Beverage Group, Inc. (NYSE American: SBEV)

Splash Beverage Group, Inc. (NYSE American: SBEV) is a publicly traded company headquartered in Fort Lauderdale, Florida. The Company is pursuing a strategic transformation toward becoming a cannabinoid health, wellness, and biopharmaceutical platform through disciplined capital allocation, strategic investments, acquisitions, and other platform-building initiatives.

About CannEpil®

CannEpil® is a pharmaceutical-grade cannabinoid combination therapy formulated as a standardised 20:1 CBD:THC oral solution and developed for the management of drug-resistant epilepsy, also referred to as refractory epilepsy. Drug-resistant epilepsy affects approximately one-third of all epilepsy patients worldwide and remains one of the largest unmet needs in neurology. The product has established regulatory and commercial access pathways across multiple jurisdictions, including Ireland, the United Kingdom, Germany, and Australia. CannEpil® is supported by real-world clinical evidence, peer-reviewed publications, EU-GMP manufacturing infrastructure, and an active FDA IND programme in the United States. CannEpil® has achieved full reimbursement status in Ireland under the Medicinal Cannabis Access Programme and recently completed the largest commercial shipment in the product's history, with 1,000 units delivered into the Irish market. The Company believes CannEpil® represents a differentiated cannabinoid therapy opportunity within the global drug-resistant epilepsy market, supported by an established clinical and commercial foundation and a defined regulatory pathway toward further development in major pharmaceutical markets.

